Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $439,756 - $610,128
22,300 Added 99.11%
44,800 $920,000
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $130,130 - $176,930
6,500 Added 40.63%
22,500 $503,000
Q1 2024

May 15, 2024

SELL
$23.82 - $32.8 $304,896 - $419,839
-12,800 Reduced 44.44%
16,000 $440,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $490,992 - $685,608
21,200 Added 278.95%
28,800 $878,000
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $199,206 - $288,414
-6,300 Reduced 45.32%
7,600 $240,000
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $466,830 - $621,405
-13,500 Reduced 49.27%
13,900 $566,000
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $642,690 - $865,026
-19,300 Reduced 41.33%
27,400 $1.02 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $1.26 Million - $2.38 Million
38,000 Added 436.78%
46,700 $1.63 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $469,104 - $623,790
8,700 New
8,700 $487,000
Q2 2020

Aug 14, 2020

SELL
$11.14 - $22.87 $1,114 - $2,287
-100 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$9.44 - $15.58 $67,968 - $112,176
-7,200 Reduced 98.63%
100 $1,000
Q4 2019

Feb 14, 2020

SELL
$10.43 - $17.67 $31,290 - $53,010
-3,000 Reduced 29.13%
7,300 $107,000
Q3 2019

Nov 14, 2019

SELL
$13.07 - $18.51 $2,614 - $3,702
-200 Reduced 1.9%
10,300 $138,000
Q2 2019

Aug 14, 2019

SELL
$13.88 - $18.41 $270,660 - $358,995
-19,500 Reduced 65.0%
10,500 $172,000
Q1 2019

May 15, 2019

BUY
$12.79 - $17.62 $383,700 - $528,600
30,000 New
30,000 $512,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $775M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.